Usher syndrome type II is an autosomal recessive disorder, characterised by stable hearing impairment from childhood and progressive retinitis pigmentosa from the late teens. Mutations in the USH2A gene, located on 1q41, were recently shown to be responsible for Usher syndrome type IIa. We have investigated the molecular pathology of Usher type II by screening the USH2A gene for mutations in 31 unrelated patients from Denmark and Norway. Besides the frequent 2299delG mutation, which accounted for 44% of the disease alleles, a heterogeneous spectrum of mutations was identified. Sixteen new, putative disease-causing mutations were detected, of which 12 were private and four were shared by unrelated patients. The disease-causing mutations were scattered throughout the gene and included six nonsense and seven missense mutations, two deletions and one small insertion. In addition, six non-pathogenic polymorphisms were identified. All missense mutations resulted in major amino acid side-chain alterations. Four missense mutations affected the N-terminal part of USH2A, whereas three missense mutations affected the laminin-type epidermal growth factor-like (LE) domain. The structural consequences of the mutations affecting the LE domain are discussed in relation to the three-dimensional structure of a LE-module of the mouse laminin γ1 chain.
Introduction
Usher syndrome (MIM 276900) constitutes a group of autosomal recessive disorders characterised by variable degrees of hearing impairment, vestibular dysfunction and progressive visual loss due to retinitis pigmentosa (RP). The condition is clinically and genetically heterogeneous and is classified into three major subtypes: Usher type I, II and III mapping to any one of nine distinct genetic loci.
Usher type II accounts for more than half of all Usher cases, with a prevalence of 2.2/100 000 in Denmark 1 and 3.6/100 000 in Norway. 2 Mutations in the USH2A gene, located on 1q41, are responsible for Usher syndrome type IIa. Three deletions were identified in the USH2A gene, of which 2299delG 3, 4 was found in 29 out of 198 disease alleles (15%).
However, Usher type II is genetically heterogeneous since approximately 12% of USH2 families do not show linkage to 1q41. 5, 6 Linkage to 3p23-24.2 was recently detected and designated USH2B. 6 The N-terminal part of the predicted 1546 amino acid residue USH2A protein shares no significant homology with known proteins. However, the deduced protein sequence contains, among others 10 laminin-type epidermal growth factor-like (LE) motifs, each about 50 amino acid residues long and arranged in tandem. The C-terminal part of the protein contains four tandem repeats with similarity to fibronectin type III elements (FN3). These protein domains are frequently observed in extracellular matrix proteins such as growth factors, receptors and cell adhesion molecules.
We have investigated the molecular pathology of Usher type II patients by screening the USH2A gene for mutations in a panel of 31 Danish and Norwegian patients. Our aim was to identify the classes of mutations which inactivate the USH2A gene or gene product and to investigate the degree of mutational heterogeneity. Such knowledge is essential for patient management and the future design of a rational molecular diagnostic strategy for Usher type II patients. Furthermore, the locations and nature of the mutations may contribute to the understanding of the structure and function of the USH2A protein. For restriction enzyme analysis of the 2299delG deletion, the missense mutations and the polymorphisms, PCR products were digested over night with the appropriate restriction enzyme and analysed by agarose gel electrophoresis. Primer sequences, conditions for PCR and restriction enzymes are listed in Table 1 .
Materials and methods

Patients
3-D protein model
All LE-domains share a common structural element primarily defined by the eight cysteines (PROSIDE document: PDOC00961). The three-dimensional structure of LE domains in mouse γ1 chain was used to predict structural 
Results
Thirty-one unrelated patients, clinically diagnosed with Usher type II were screened for the 2299delG mutation, 3 revealing six homozygotes and 12 heterozygotes. Twenty-five patients who were not homozygous for 2299delG, were screened for mutations in the coding region of the USH2A gene. Exon 2 throughout exon 21 were amplified by PCR from genomic DNA and subjected to automated DNA sequencing. Sixteen different putative disease-causing mutations were identified ( Table 2 and Figure 1 ). In addition, six polymorphisms not associated with disease were detected ( Table 3) . Disease-alleles were identified in 27 out of 31 patients. Eight patients were homozygotes, 19 were compound heterozygotes, among whom nine disease-alleles remained unidentified (Table 4) .
Mutations identified
The mutations, their predicted effect on the USH2A gene and their frequencies are summarized in Tables 2, 3 and 4. Their respective locations within USH2A are indicated in Figure 1 . The genotypes of the Usher type IIa patients are listed in Table 4 .
Nonsense mutations
Six different mutations leading to premature stop codons were found in six patients, all due to C → T transitions. Four mutations, resulting in the substitution of arginines for stop codons, were detected at CpG dinucleotides, known to be hot spots for transitions. 10 Two unrelated Norwegian patients, N1
and N3, had the same mutation at nucleotide 100 (R34X). The mutation at nt. 2797 (Q933X) was identified in two unrelated Danish patients, D21 and D7. The transitions at nucleotide positions 187, 1876, 2023 and 3883 (R63X, D626X, Q675X and R1295X, respectively) were all private.
Deletions and insertion
Besides 2299delG, two deletions and one insertion were predicted to lead indirectly to premature stop codons through shift in the translational reading frame. In two unrelated Danish patients, D14 and D15, a 4 bp insertion was identified, which shifts the reading frame after codon 307 ending at a stop codon at position 323. Patient D3 was homozygous for 2878delAA, which results in a frameshift after codon 959 and ending at a UAA stop codon, three residues downstream. Likewise, the 1965delT mutation causes a frameshift after codon 654 introducing an aberrant amino acid sequence that terminates at a UGA stop codon 100 residues downstream.
Missense mutations
Seven different missense mutations were identified in nine patients. None of the 100 Norwegian control alleles contained the C163Y, N346H, R334W, C536R, G713R or C759F substitutions, whereas the V230M substitution was identified in 1 out of 100 control chromosomes. The N346H substitution was detected in two unrelated patients, D20 and N7, from Denmark and Norway, respectively. Interestingly, in patient D21, a C163Y replacement as well as two different Mutation occurs at CpG dinucleotide; FS = frame shift.
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nonsense mutations were identified. However, due to lack of DNA from close relatives the cis-trans problem could not be solved. The V230M, R334W, C536R, G713R, and C759F substitutions were all private.
Polymorphisms and unclassified variants
In addition to the putative disease causing mutations, five exonic and one intronic polymorphism were identified. Three of the exonic mutations were silent (504A/G, 1419C/T and 4371A/G) and two resulted in amino acid changes (A/T125 and K/R1486). The IVS-8T/G mutation was located in a polypyrimidine tract in close proximity to the acceptor site of intron 8. A similar T to G transversion was reported to affect splicing efficiency in the human -globin transcript. 11 However, because of homozygosity in several normal healthy individuals, all six mutations were excluded from being disease-causing. The observed frequencies of these polymorphisms among Norwegian normal chromosomes ranged from 0.03 to 0.36 (Table 2) . Furthermore, four intronic mutations were observed in several patients. Because, they were presumed to have no effect on RNA-processing they were not tested in the normal control panel but instead regarded as unclassified variants. 
Discussion
We have identified pathogenic USH2A alleles in 27 unrelated Usher type II patients. Putative disease-causing mutations were identified in 45 of the 62 disease alleles studied (73%).
Sixteen new disease-causing mutations were characterised. These included six nonsense, seven missense, two deletions and one insertion. In addition, five exonic and one intronic non-pathogenic polymorphisms were identified.
Characteristics of the mutations
Since Usher type II is a recessive disorder, the mutations were predicted to be pathogenic due to loss of USH2A function. The nonsense mutations, deletions and insertions leading directly or indirectly to premature termination of translation were predicted to disrupt the function of the USH2A protein.
All missense mutations resulted in major changes in the sidechain properties of the corresponding amino acid residue. Regarding the C163Y, V230M, R334W and N346H substitutions, they are all located in the N-terminal part of the protein; however, their disruptive effect on the function of the USH2A protein is not yet known. Among the seven missense mutations reported here, three (C536R, C759F and G713R) result in changes of highly conserved residues in the laminin-type epidermal growth factor-like (LE) domain. Hence, Usher type II is caused both by mutations that in homozygous or compound heterozygous states cause complete absence, as well as mutations that cause alterations in single amino acid side chains of the 1546 a.a., USH2A protein.
Structural consequences of the mutations affecting the LE domains
The availability of the three-dimensional structure of the mouse laminin γ1 chain is an important source for predicting the consequences of amino acid substitutions in the LE domains. Based on crystallographic data the LE domains have been shown to be independently folded protein modules. They are described as four looped structures (a-d), stabilised by four disulfide bridges (Figure 2) . 8, 12 The modules have a distinct variability with respect to the size, structure and arrangement of the loops. The eight invariant cysteine residues principally define the primary structure of the LE domain and form disulfide bonds with the following pattern: Cys1-Cys3 (loop a), Cys2-Cys4 (loop b), Cys5-Cys6 (loop c) and Cys7-Cys9 (loop d) ( Figure 2 ). In addition, loop d of the preceding LE module and the loop b of the following LE module form a hook-like association through hydrogen bonds and hydrophobic interactions. 8 The C536R and C759F
substitutions disrupt the disulfide bond formation to C520 (C2) and C747 (C1), respectively ( Figure 2 ). Both substitutions were predicted to result in abnormal folding of the LE domain, thereby affecting the functional properties of the protein. The G713R replacement of the hydrophobic side chain of glycine with the positive charged side of arginine, is likely to strongly destabilise the loop structure as suggested by the conservation of the glycine in the multiple alignment ( Figure 2 ) The LE domains are thought to function as a rigid, rod-shaped, mechanical spacer that keeps the N-terminal and C-terminal regions apart. 12 In addition, the LE domains may be involved directly in inter-molecular interactions. Thus, disruption of rigidity as well as disruption of binding properties could explain loss of function of these mutant proteins.
Limitations in mutation detection
Putative disease-causing mutations were identified in 27 out of 31 (87%) patients studied. In four patients, no alterations were found which could be associated with disease and in nine patients the second disease allele remained unidentified. This relates to general problems in mutation detection such as technical limitations and genetic heterogeneity. Although splice site mutations have been reported to account for 15% of all mutations involved in human genetic disease, 13 no putative splice site mutations were observed in this study, despite that all PCR primers were designed to include all exon/intron boundaries. Likewise, in human genetic disease large rearrangements such as deletions and insertions In four patients who met the clinical criteria for Usher type II no USH2A mutations could be identified. One of these patients belong to a previously characterised Norwegian Saami family in which the segregation of 1q41 markers are consistent with the USH2A locus (lod score 3.09). 14 We cannot exclude the possibility that another Usher locus could be closely linked to the USH2A locus. As for the remaining three patients linkage to USH2A has not been confirmed. To date, two genes have been found to be responsible for Usher syndrome. These are MYO7A and USH2A in Usher type I and Usher type II, respectively. So far, 46 mutations likely to be disease-causing have been identified in MYO7A and no single mutation appears to predominate, [15] [16] [17] [18] [19] [20] except for a probable founder mutation (C31X) which accounted for 50% of the mutations in the Danish Usher type I patients. 20 In Usher type IIa patients, however, the 2299delG mutation, reported in patients from Scandinavia (Denmark, Norway and Sweden), Northern and Southern Europe, North America, UK and China dominate the mutational spectrum (frequency ranging from 0.15 to 0.44).
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The 2299delG mutation occurs at high and similar frequency among Danish (0.45) and Norwegian (0.42) Usher IIa patients. Preliminary results suggest that Danish and Norwegian 2299delG alleles share the same intragenic haplotype based on six SNP markers but deviate with respect to flanking microsatellite markers (results not shown). Further haplotype analysis is required to determine whether the 2299delG has spread by founder effect and/or recurrent mutational events.
